Search Legislation

The Misuse of Drugs Regulations 2001

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about opening options

Opening OptionsExpand opening options

Changes over time for: PART I

 Help about opening options

Changes to legislation:

There are currently no known outstanding effects for the The Misuse of Drugs Regulations 2001, PART I. Help about Changes to Legislation

PART IU.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1.  The following substances and products, namely—U.K.

  • Alprazolam

  • Aminorex

  • Bromazepam

  • Brotizolam

  • Camazepam

  • Chlordiazepoxide

  • [F11–(3–chlorophenyl)piperazine]

  • [F11–(3–chlorophenyl)–4–(3–chloropropyl)piperazine]

  • Clobazam

  • Clonazepam

  • Clorazepic acid

  • Clotiazepam

  • Cloxazolam

  • Delorazepam

  • Diazepam

  • Estazolam

  • Ethyl loflazepate

  • Fencamfamin

  • Fenproporex

  • Fludiazepam

  • Flurazepam

  • Halazepam

  • Haloxazolam

  • F2...

  • F3...

  • Ketazolam

  • Loprazolam

  • Lorazepam

  • Lormetazepam

  • Medazepam

  • Mefenorex

  • Mesocarb

  • F4...

  • Nimetazepam

  • Nitrazepam

  • Nordazepam

  • Oxazepam

  • Oxazolam

  • Pemoline

  • Pinazepam

  • Prazepam

  • Pyrovalerone

  • [F5Remimazolam]

  • Tetrazepam

  • Triazolam

  • [F6Xylazine]

  • N-Ethylamphetamine

  • [F7Zaleplon]

  • [F8Zolpidem]

  • [F9Zopiclone]

Textual Amendments

F8Word in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(b)

2.  Any stereoisomeric form of a substance specified in paragraph 1.U.K.

3.  Any salt of a substance specified in paragraph 1 or 2.U.K.

4.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.U.K.

[F105.  A liquid formulation—U.K.

(a)containing a botanical extract of cannabis—

(i)with a concentration of not more than 30 milligrams of cannabidiol per millilitre, and not more than 30 milligrams of delta-9-tetrahydrocannabinol per millilitre, and

(ii)where the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3,

(b)which is dispensed through a metered dose pump as a mucosal mouth spray, and

(c)which was approved for marketing by the Medicines and Healthcare Products Regulatory Agency on 16th June 2010]

Back to top

Options/Help